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Simple Summary: Here we show that a protein called C/EBPδ is present in healthy pancreas tissue
but almost absent in pancreas tumors. Patients with less C/EBPδ in their tumors had the most
metastases and the worst survival chances, showing that C/EBPδ has tumor-suppressive properties in
pancreatic cancer. In this study, we reactivated C/EBPδ in pancreatic cancer cells in vitro and observed
a reduction in cell proliferation in a 2-dimentional and 3-dimensional space. This implies that tumor
cells grow slower when C/EBPδ is activated and they are likely also less capable to escape the primary
tumor in order to form metastases. Conversely, when we deleted C/EBPδ in pancreatic cancer cells,
we observed accelerated growth. We suggest that reactivating C/EBPδ can suppress tumor growth
and formation of metastases, thereby improving patient survival.
Abstract: CCAAT/enhancer-binding protein δ (C/EBPδ) is a transcription factor involved in growth
arrest and differentiation, which has consequently been suggested to harbor tumor suppressive
activities. However, C/EBPδ over-expression correlates with poor prognosis in glioblastoma
and promotes genomic instability in cervical cancer, hinting at an oncogenic role of C/EBPδ in these
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contexts. Here, we explore the role of C/EBPδ in pancreatic cancer. We determined C/EBPδ expression
in biopsies from pancreatic cancer patients using public gene-expression datasets and in-house tissue
microarrays. We found that C/EBPδ is highly expressed in healthy pancreatic ductal cells but lost in
pancreatic ductal adenocarcinoma. Furthermore, loss of C/EBPδ correlated with increased lymph node
involvement and shorter overall survival in pancreatic ductal adenocarcinoma patients. In accordance
with this, in vitro experiments showed reduced clonogenic capacity and proliferation of pancreatic
ductal adenocarcinoma cells following C/EBPδ re-expression, concurrent with decreased sphere
formation capacity in soft agar assays. We thus report a previously unrecognized but important
tumor suppressor role of C/EBPδ in pancreatic ductal adenocarcinoma. This is of particular interest
since only few tumor suppressors have been identified in the context of pancreatic cancer. Moreover,
our findings suggest that restoration of C/EBPδ activity could hold therapeutic value in pancreatic
ductal adenocarcinoma, although the latter claim needs to be substantiated in future studies.
Keywords: CCAAT/enhancer-binding protein delta; CEBPD; pancreatic ductal adenocarcinoma;
PDAC; tumor suppressor; ampullary carcinoma; intrapancreatic cholangiocarcinoma
1. Introduction
Pancreatic cancer is a devastating disease with a survival outcome that is the worst of all human
cancers [1]. The 5-year survival rate upon diagnosis is a little over 9% and overall mortality reaches
99% [2,3]. Due to the late onset of symptoms, only 15–20% of patients present with resectable disease,
whereas the remaining patients present with metastatic or locally advanced disease, which cannot be
resected. The median survival of the selected group of resectable patients, however, increases only to
around 23 months whereas 5-year survival rates remain below 20% [4–6]. Eventually, the majority of
these patients with a resectable primary tumor will succumb due to metastatic disease as well [7]. Thus,
there is a clear clinical need to better understand the processes that drive pancreatic cancer and guide
the development of novel avenues for rational treatment of this disease.
Ninety-five percent of pancreatic cancers arise from the exocrine compartment of the pancreas [8].
Of these exocrine tumors, pancreatic ductal adenocarcinoma comprises about 90% of all cases.
In addition to pancreatic ductal adenocarcinoma, ampullary carcinoma and intrapancreatic
cholangiocarcinoma may also be present within the pancreas due to their anatomical proximity,
although these tumors are strictly taken no pancreatic cancers [9–11]. Ampullary carcinoma, with an
incidence of around 0.6 cases in 100,000, arises in the ampulla of Vater, which is where the bile duct
and pancreatic duct connect with the duodenum [9]. Intrapancreatic cholangiocarcinoma, with an
incidence rate of 1–2 cases per 100,000, arises from epithelial cells of the bile duct (cholangiocytes)
and is known as intrapancreatic bile duct cancer when it occurs where the bile duct passes
through the pancreas [10,11]. The symptoms and pathology of intrapancreatic cholangiocarcinoma
and pancreatic ductal adenocarcinoma are very similar and consequently these two types are difficult
to distinguish.
Only a limited number of tumor suppressor genes have been formally established in pancreatic
ductal adenocarcinoma. Mutations in genes such as TP53, SMAD4, PTEN, and CDKN2A are present
in over 70% of pancreatic ductal adenocarcinomas, and mutations in these tumor suppressors are
well known to drive tumor progression. As opposed to their clear biological relevance, mutations
in tumor suppressor genes typically are of limited therapeutic value [12,13]. To improve patient
treatment, the identification of tumor suppressor genes that could serve as therapeutic targets is
therefore eagerly awaited.
CCAAT/enhancer-binding protein δ (C/EBPδ) is a member of the C/EBP superfamily of transcription
factors, which consists of six unique members (α, β, γ, δ, ε and ζ) [14]. Soon after its discovery,
C/EBPδ was implied to act as a tumor suppressor by inducing growth arrest and differentiation in
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breast cancer [15]. Indeed, C/EBPδ expression promotes CDC27 expression, leading to increased
degradation of the cell cycle proteins cyclin D1, cyclin B1, Plk-1, and Skp2 [16]. Furthermore,
expression of C/EBPδ is associated with downregulation of c-Myc and cyclin E, and upregulation
of the cyclin-dependent kinase inhibitor p27 in the leukemia cell lines K562 and KCL22, leading
to growth arrest and differentiation [17]. In A431 cervical cancer cells, C/EBPδ expression leads
to the induction of apoptosis via the transcriptional regulation of the pro-apoptotic genes PPARG2
and GADD153 [18]. Moreover, C/EBPδ is involved in the regulation of pro-apoptotic gene expression
and growth arrest during mammary gland involution [19,20]. In line with these data, C/EBPδ
indeed acts as a tumor suppressor in breast cancer [21–23], ovarian serous carcinoma [24], cervical
carcinoma [25], leukemia [26] and hepatocellular carcinoma [27,28].
In contrast to the presumed tumor suppressor role of C/EBPδ, several studies suggest that C/EBPδ
may actually drive tumor progression in certain cancers. Indeed, C/EBPδ over-expression correlates
with poor prognosis in glioblastoma [29]; it is required for efficient metastatic growth of mammary
tumors [30], and drives proliferation and invasiveness of urothelial carcinoma cells, thereby driving
metastatic disease leading to a reduced disease-specific survival [31]. Finally, C/EBPδ promotes
tumorigenesis in the cervix by inducing aneuploidy and centromere abnormalities [32].
Taken together, the role of C/EBPδ in tumor biology seems more complex than originally anticipated
and it does not seem to be a generic tumor suppressor. Instead, C/EBPδmay either suppress or promote
tumor growth in a context specific manner. Here, we extend this notion by exploring the potential
relevance of C/EBPδ in pancreatic cancer. We show that, despite its obvious importance for restraining
cancer growth in a variety of systems, C/EBPδ takes on a tumor suppressive role in pancreatic ductal
adenocarcinoma, while such effects remain insignificant, albeit not completely absent, in ampullary
carcinoma or intrapancreatic cholangiocarcinoma. Moreover, we show that re-expressing C/EBPδ limits
pancreatic cancer cell proliferation and future studies should elucidate whether it is of therapeutic
interest in the treatment of this devastating disease.
2. Results
2.1. CEBPD mRNA Expression Is Decreased in Pancreatic Ductal Adenocarcinoma Tissue
To assess whether C/EBPδmay act as a tumor suppressor in pancreatic cancer, we first analyzed
CEBPD mRNA expression levels in pancreatic ductal adenocarcinomas and in adjacent control tissue
in publicly available gene expression datasets (GSE62452 [33] and GSE16515 [34]). As shown in
Figure 1, CEBPD mRNA expression was observed in both tumor and non-tumor tissue in both datasets
analyzed. Interestingly, however, CEBPD expression was decreased in tumor tissue as compared to
the control tissue in both the GSE62452 (Figure 1A) and GSE16515 (Figure 1B) dataset. Subsequently,
patients of the datasets were dichtomerized into CEBPD-high and CEBPD-low groups whereupon
differential gene expression analysis between these groups revealed enhanced expression of genes
from published proliferation signatures [35,36] in patients of the CEBPD-low group opposed to
the CEBPD-high group (data for GSE62452 shown in Figure 1C,D and Table S1). To corroborate these
findings and provide statistics, we next performed gene set enrichment analyses of the proliferation
signatures on the pancreatic cancer datasets. Samples were dichotomized by median CEBPD expression,
and analysis showed a significant association with both signatures in the datasets (Figure 1E for
the Ben-Porath proliferation gene set [35] and Figure 1F for the Chiang gene set [36], respectively,
in GSE62452).
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Figure 1. Analysis of publicly available datasets reveals C/EBPδ as a potential tumor suppressor in
pancreatic ductal adenocarcinoma. (A,B) CEBPD gene expression in pancreatic ductal adenocarcinoma
biopsies and adjacent healthy pancreatic tissue biopsies derived from GSE62452 (A) and GSE16515 (B).
** p < 0.01, *** p < 0.001 compared to healthy control tissue. Lines indicate the mean ± SEM.
(C,D) Volcano plot of statistical significance against fold change between high and low CEBPD samples.
Each data point represents a gene, while genes from the Ben-Porath [35] (C) or Chiang [36] (D)
proliferation gene signatures are highlighted in red. Negative fold changes imply higher expression
of a gene in the CEBPD-low group and vice versa. (E,F) Gene set enrichment analysis (GSEA) using
the Ben-Porath (E) or Chiang (F) proliferation gene signatures on patients with high or low CEBPD
expression levels in GSE62452. GSEA: gene set enrichment analysis, NES: normalized enrichment score,
FDR: false discovery rate.
2.2. C/EBPδ Protein Levels Are Decreased in Pancreatic Ductal Adenocarcinoma but Not in Ampullary
Carcinoma or Intrapancreatic Cholangiocarcinoma
C/EBPδ is a ubiquitously expressed transcription factor which is not specific to epithelial (tumor)
cells but also expressed in cell types of the stromal compartment including pancreatic stellate
cells [37]. Indeed, CEBPD expression levels correlate with stromal gene signatures in five out of six
publicly available datasets containing pancreatic ductal adenocarcinoma (PDAC) samples [34,38–42]
as determined using ESTIMATE [43] (Table S2 and Figure S1). Moreover, for transcriptional activity
of C/EBPδ, only nuclear expression is relevant and gene expression levels of tissue biopsies such as
those used in the bioinformatics experiments described above may consequently not accurately reflect
the C/EBPδ activity that is relevant for tumor cell biology. To circumvent these confounding effects of
whole biopsy gene expression analysis, we subsequently immunohistochemically analyzed nuclear
C/EBPδ protein levels in tumor cells of a cohort of 67 pancreatic ductal adenocarcinoma patients
using normal duct epithelium as control. C/EBPδwas highly expressed in normal, non-tumorigenic,
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pancreatic ductal cells (Figure 2A,B). The vast majority of normal pancreatic ductal cells showed strong
nuclear C/EBPδ staining. Interestingly, C/EBPδ expression was significantly decreased in pancreatic
ductal adenocarcinoma cells (Figure 2C–G). Although some cytoplasmic staining was still observed in
pancreatic ductal adenocarcinoma biopsies, most of the tumor cell nuclei were negative for C/EBPδ or
the intensity was very much decreased compared to normal tissue.
Figure 2. C/EBPδ expression is decreased in the nuclei of pancreatic ductal adenocarcinoma cells.
Immunohistochemical staining of C/EBPδ shows strong expression in healthy pancreatic tissue (A,B)
and decreased (C,D) or no expression (E,F) in pancreatic ductal adenocarcinoma. Representative
tumor nuclei are indicated with black arrowheads. Quantification of nuclear C/EBPδ expression
levels in healthy control tissue (G–I), pancreatic ductal adenocarcinoma (G), ampullary carcinoma
(H) and intrapancreatic cholangiocarcinoma (I). *** p < 0.001 compared to healthy control tissue.
Lines indicate the mean ± SEM. PDAC: pancreatic ductal adenocarcinoma, AC: ampullary carcinoma,
IP CCA: intrapancreatic cholangiocarcinoma. Scale bars: 20 µm.
To determine whether the observed decrease in nuclear C/EBPδ expression in pancreatic cancer
is specific to pancreatic ductal adenocarcinomas or whether it is a more general phenomenon,
we also determined nuclear C/EBPδ expression levels in ampullary carcinoma and intrapancreatic
cholangiocarcinoma. We found that C/EBPδ expression levels were relatively low in the nuclei of
normal intestinal epithelial cells within the ampulla of Vater (Figure 2H) and in normal cholangiocytes
(Figure 2I) compared to normal pancreatic ductal cells. Moreover, nuclear C/EBPδ expression was
not further decreased in tumor cells of these cancer types and semi-quantitative analysis of C/EBPδ
expression levels showed no significant difference between normal and tumor cell nuclei in these
patients (Figure 2H,I).
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2.3. C/EBPδ Protein Expression Is Associated with Regional Lymph Node Involvement and Correlates with
Overall Survival in Pancreatic Ductal Adenocarcinoma
To assess the potential clinical relevance of reduced C/EBPδ expression in pancreatic ductal
adenocarcinoma, we first determined whether C/EBPδ correlated with lymph node involvement in
these patients. As shown in Figure 3A and Table 1, C/EBPδ expression in the nuclei of primary
tumors was significantly decreased in patients with tumor cell positive regional lymph nodes (N1)
compared to patients without tumor cell positive regional lymph nodes (N0). This association of
C/EBPδ protein levels with N-status was absent in ampullary carcinoma (Figure 3B) and intrapancreatic
cholangiocarcinoma (Figure 3C). In line with metastasis to local lymph nodes, decreased nuclear
C/EBPδ expression was also significantly correlated with shorter overall survival in pancreatic ductal
adenocarcinoma patients (Figure 3D). Median survival of pancreatic ductal adenocarcinoma patients
in the lower half of C/EBPδ expression was 16.9 months, whereas median survival of patients in
the upper half of C/EBPδ expression was 22.2 months (p < 0.05). Compared to pancreatic ductal
adenocarcinoma, patients with ampullary carcinoma (Figure 3E) or intrapancreatic cholangiocarcinoma
(Figure 3F) showed a longer median overall survival of 49.9 and 24.4 months, respectively (versus
18.3 months for the pancreatic ductal adenocarcinoma patients). As expected based on similar C/EBPδ
expression and the lack of association with regional lymph node involvement, C/EBPδ expression
also did not correlate significantly with overall survival in ampullary carcinoma and intrapancreatic
cholangiocarcinoma. These results lead to the notion that C/EBPδ may act as a tumor suppressor
in pancreatic ductal adenocarcinoma, while this relation is not observed in ampullary carcinoma or
intrapancreatic cholangiocarcinoma.
Figure 3. C/EBPδ expression correlates with regional lymph node metastasis and overall survival
in pancreatic ductal adenocarcinoma patients. (A–C) C/EBPδ expression levels in patients with
and without regional lymph node metastasis (N0: negative regional lymph nodes, N1: positive regional
lymph nodes) in pancreatic ductal adenocarcinoma (A), ampullary carcinoma (B) and intrapancreatic
cholangiocarcinoma (C). (D–F) Overall survival in pancreatic ductal adenocarcinoma (D), ampullary
carcinoma (E) and intrapancreatic cholangiocarcinoma (F) in different groups of C/EBPδ expression
levels.Vertical black bars in Kaplan-Meier plots represent censored patients. ns: not significant.
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Table 1. N-status correlates to C/EBPδ protein expression in pancreatic ductal adenocarcinoma patients.
N-Status
C/EBPδ Expression
Low High
(N = 47) (N = 20)
N0 7 8
N1 40 12
Fisher’s exact test p = 0.029
Median survival (months) 16.9 22.2
2.4. C/EBPδ Modulates Oncogenesis of Pancreatic Ductal Adenocarcinoma Cells
2.4.1. C/EBPδ Over-Expression Reduces Proliferation of Pancreatic Ductal Adenocarcinoma Cells
To further validate the potential tumor-suppressive effects of C/EBPδ in pancreatic ductal
adenocarcinoma, we conducted in vitro clonogenic assays with two commonly used pancreatic
ductal adenocarcinoma cell lines, PANC-1 and MIA PaCa-2. From publicly available mRNA expression
datasets, we know that both these cell lines show low baseline expression levels of CEBPD which is in
line with the low expression levels observed in pancreatic ducal adenocarcinoma patients, making
them a solid model for C/EBPδ over-expression studies. First, we assessed the effect of transient
C/EBPδ over-expression on the clonogenic capacity of PANC-1 cells. To this end, 100 control- or
CEBPD-transfected cells were seeded into 24-well plates after which colony formation was observed
over time. As shown in Figure 4A, we observed a significant reduction in clonal outgrowth by
C/EBPδ over-expressing cells as compared to control cells (p < 0.005). To corroborate these findings,
we next seeded single control- or CEBPD-transfected cells in 96-well plates. Similar to the 100 cells per
well approach, CEBPD over-expression decreased the clonogenic capacity of PANC-1 cells. Indeed,
CEBPD-over-expressing cells showed a clonogenic capacity of 8% (N = 23 colonies out of 288 single cells)
as compared to 16% in control-transfected cells (N = 46 colonies out of 288 single cells), constituting a
decrease of 50% in clonogenic capacity (χ2 test, p = 0.0032).
As C/EBPδ is expected to dilute out in transient transfection experiments, we next performed
stable transfection experiments. To this end, PANC-1 and MIA PaCa-2 cells were transduced with a
CEBPD-IRES-EGFP over-expression plasmid; after which, cells were sorted into three fractions based
on eGFP fluorescence (Figure 4B). Importantly, both C/EBPδ and eGFP were indeed over-expressed
in transduced cells (Figure 4C) and CEBPD expression correlated with EGFP expression (Figure 4D).
Subsequent clonogenic experiments with 500 transduced cells of each fraction seeded in 12-well
plates confirmed the transient transfection experiments by showing that C/EBPδ expression was
negatively correlated with colony formation in both cell lines (PANC-1 low expression: 114 colonies;
intermediate expression: 83 colonies; high expression: 52 colonies. MIA PaCa-2 low expression:
75 colonies; intermediate expression: 56 colonies; high expression: 41 colonies) (Figure 4E,F).
Altogether, these in vitro experiments imply that C/EBPδ indeed limits the growth of pancreatic
ductal adenocarcinoma cells.
2.4.2. A Tet-on System Reveals Dose-Dependent Effects of C/EBPδ on Proliferation and Clonogenicity
To widen our understanding of the effects of C/EBPδ on pancreatic adenocarcinoma cells, we turned
to a doxycycline-inducible Tet-On system. As shown in Figure 5A–F, this system permits tightly
controlled expression of C/EBPδ with induction levels at the 2000 ng/mL doxycycline dose, mimicking
the fold-change in protein expression observed in tumor versus normal patient samples. As observed
with constitutive over-expression, controlled over-expression of C/EBPδ curbed proliferation of
pancreatic adenocarcinoma cells. Interestingly, subjecting the cells to a concentration of 100 ng/mL
doxycycline, which minimally induces C/EBPδ, already moderately reduced proliferation of PANC-1
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while a concentration of 2000 ng/mL significantly reduced proliferation in both PANC-1 and MIA
PaCa-2 (Figure 5G,H).
Figure 4. C/EBPδ over-expression inhibits clonogenicity in PANC-1 and MIA PaCa-2 cells. (A) Average
number of colonies grown out from 100 C/EBPδ-over-expressing or control-transfected PANC-1 cells per
well in three independent experiments (N = 21). Lines indicate the mean± SEM. ** p < 0.005. Out of 2100
control-transfected cells, 356 grew into a colony. Only 205 out of 2100 C/EBPδ over-expressing cells grew
out a colony. (B) Histogram and gating of CEBPD-IRES-EGFP-transduced MIA PaCa-2 cells. (C) Western
blot showing over-expression of C/EBPδ and eGFP protein after transfection. The uncropped blots are
provided in Figure S2. (D) CEBPD and EGFP mRNA expression of CEBPD-IRES-EGFP-transduced
cells sorted by EGFP-fluorescence. Quantitative RT-PCR confirmed elevated CEBPD mRNA expression
in cells expressing high EGFP mRNA (MIA PaCa-2: R2 = 0.9975, * p < 0.05; PANC-1: R2 = 0.9724,
p = 0.0531). (E) Clonogenic assay of PANC-1 and MIA PaCa-2 cells expressing C/EBPδ at varying levels.
(F) C/EBPδ expression correlates with colony formation efficiency. Plotting the number of colonies from
Figure 4E against the respective CEBPD mRNA expression shows a dependency of colony formation
efficiency on CEBPD levels in PANC-1 and MIA PaCa-2 cells.
Next, we assessed the limiting effects of C/EBPδ on colony formation of pancreatic adenocarcinoma
cells. Seeding single cells in 96-well plates, we found that 2000 ng/mL doxycycline reduced single
cell outgrowth by 32% in MIA PaCa-2 and by 12% in PANC-1cells (data not shown). The observed
reduction in clonogenicity was lower compared to that seen in the constitutive system shown in
Figure 4 which is well in accordance with the difference in C/EBPδ expression between the two systems
and again emphasizes that these effects are dose-dependent on C/EBPδ.
In addition to two-dimensional clonogenic and proliferation assays, we next assessed
anchorage-independent growth in three-dimensional soft agar sphere formation assays.
This assay constitutes a well-recognized measure of stemness and malignant potential owed to
anchorage-independent out-growth of a single cell [44]. As in two-dimensional clonogenic assays,
we also observed a decrease in tumor sphere formation when comparing doxycycline-treated C/EBPδ
over-expressing cells to untreated low C/EBPδ expressing cells. Interestingly, 100 ng/mL doxycycline
already significantly limited sphere formation in PANC-1 cells but had no effect in MIA PaCa-2 cells.
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The 2000 ng/mL doxycycline dose again drastically suppressed sphere formation by PANC-1 and also,
to some extent, reduced the number of spheres formed by MIA PaCa-2 cells although this difference
did not reach significance (Figure 5I,J).
Figure 5. Doxycycline dose-dependent induction of C/EBPδ regulates proliferation and tumor sphere
formation. (A) Single clones of MIA PaCa-2 cells, transduced with a doxycycline-inducible C/EBPδ
over-expression plasmid, show increased C/EBPδ mRNA levels upon induction. (B) C/EBPδ induction
in MIA PaCa-2 cells over time. The uncropped blots are provided in Figure S3A (C–F) Doxycycline
dose-dependently induces C/EBPδ in both transduced MIA PaCa-2 and PANC-1 cells. The uncropped
blots are provided in Figure S3B,C. (G,H) Proliferation is mildly decreased by 100 ng/mL and significantly
reduced by 2000 ng/mL doxycycline in PANC-1 (** p = 0.0012) and MIA PaCa-2 (** p = 0.0078) cells.
(I,J) Tumor sphere formation in soft agar is significantly reduced by 100 and 2000 ng/mL doxycycline in
PANC-2 (*** p = 0.0004). A similar yet not significant trend is observed in MIA PaCa-2 with 2000 ng/mL
doxycycline. Dox: Doxycycline. n.s.: not significant, *** p < 0.001.
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2.4.3. Silencing C/EBPδ Enhances Proliferation of Pancreatic Ductal Adenocarcinoma Cells
Considering the finding that over-expressing C/EBPδ reduces the proliferation of pancreatic
ductal adenocarcinoma cells, thereby decreasing their malignant potential, we next asked whether
silencing C/EBPδwould conversely trigger proliferation. As both PANC-1 and Mia PaCa-2 cells already
express very low or undetectable C/EBPδ levels, we turned to Capan-2 cells that, according to public
gene expression datasets, show the highest CEBPD levels of all routinely used pancreatic cancer cell
lines (Figure S4) [45,46]. Interestingly, shRNA CEPBD-silenced Capan-2 cells (silencing efficiency in
Figure 6A) indeed showed increased proliferation rates as compared to control-silenced cells (Figure 6B).
Notably, more efficient silencing corresponded to progressively increased proliferative capabilities,
underscoring the dose-dependent effect of C/EBPδ on pancreatic adenocarcinoma cell behavior.
Figure 6. Silencing C/EBPδ enhances proliferation of Capan-2 cells. (A) Quantitative RT-PCR shows
decreased levels of CEBPD mRNA in Capan-2 cells stably expressing shRNAs against CEBPD.
(p = **0.0058, *0.0429, *0.0338 and **0.001 for shCTRL vs. shCEBPD #1, #2, #2 and #4, respectively).
(B) Proliferation of CEBPD-silenced Capan-2 cells is significantly increased compared to control cells.
(p = **0.0013, *0.011, *0.0146 and **0.0013 for shCTRL vs. shCEBPD #1, #2, #2 and #4, respectively).
3. Discussion
C/EBPδ has been found to negatively affect tumor growth by inducing growth arrest
and differentiation [21–28]. Recently, however, C/EBPδ was also suggested to drive tumor progression
and/or metastasis in certain tumor types [29–32], suggesting that C/EBPδ may either suppress or
promote tumor progression in a context specific manner. Here, we explore the importance of C/EBPδ
in pancreatic cancer and show that C/EBPδ harbors tumor suppressor activity in pancreatic ductal
adenocarcinoma and that re-expressing C/EBPδ in pancreatic adenocarcinoma cells curbs clonogenicity
and proliferation.
Data mining of publicly available microarray datasets showed that CEBPD gene expression
is significantly decreased in pancreatic ductal adenocarcinomas versus healthy pancreatic tissue.
Although of obvious interest, whole tumor biopsy CEBPD expression levels do not necessarily
correspond to C/EBPδ activity in tumor cells. In addition to confounding expression of CEBPD
in stromal cells, expression levels in whole tumor biopsies may also not fully represent nuclear
C/EBPδ activity. Subsequent immunohistochemical analyses of tissue arrays underscore this notion
and indeed show both stromal and cytoplasmic staining. Of interest, in pancreatic tissue biopsies,
healthy ductal cells express high nuclear levels of C/EBPδwhich is at odds with the general notion that
C/EBPδ expression is typically low under normal conditions [47]. More importantly, C/EBPδ levels are
dramatically reduced in ductal adenocarcinoma cells as compared to normal ductal cells. As C/EBPδ
induces growth arrest [16,17], it is tempting to speculate that the loss of C/EBPδ conversely facilitates
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tumorigenesis. Such a role of C/EBPδ would be in line with previous studies showing that C/EBPδ is a
tumor suppressor in leukemia, breast cancer, hepatocellular carcinoma and cervical cancer [21–28].
We were able to confirm that C/EBPδ expression is low in MIA PaCa-2 and PANC-1, two commonly
used pancreatic ductal adenocarcinoma cell lines. This is in line with our observations in pancreatic
cancer patients and with a potential role of C/EBPδ as a tumor suppressor in pancreatic cancer.
More importantly, their low C/EBPδ expression makes these cells suitable model systems for C/EBPδ
re-expression studies with the assumption that rescuing C/EBPδ expression would reduce their
tumorigenic capacity in case C/EBPδ acts as a genuine tumor suppressor. PANC-1 and MIA PaCa-2 cells
indeed showed decreased proliferation and clonogenicity upon C/EBPδ re-expression. Additionally,
these effects were dose dependent, implying a relation between tumorigenicity and C/EBPδ expression
levels. Conversely, shRNA-dependent silencing of C/EBPδ enhances proliferation in a dose-dependent
manner strongly suggesting that C/EBPδ expression levels negatively correlate with the proliferative
capacity of pancreatic ductal adenocarcinoma cells.
Next to driving proliferation and clonogenicity of pancreatic ductal adenocarcinoma cells,
loss of C/EBPδ also seems to promote anchorage-independent growth. This clonogenic capacity
in a three-dimensional, anchorage-free environment is considered a key hallmark of oncogenic
transformation and is considered the most accurate and stringent in vitro assay for detecting malignant
transformation of cells. We found a marked reduction in the number of spheres formed by two
pancreatic adenocarcinoma cell lines upon re-expression of C/EBPδ. Interestingly, although C/EBPδ
re-expression limits sphere formation in both PANC-1 and MIA PaCa-2 cells, PANC-1 cells appear to
be more susceptible to reversing oncogenic properties upon C/EBPδ induction. Although the precise
mechanism underlying the reduction in anchorage-independent growth of pancreatic adenocarcinoma
cancer cell remains to be established, it is tempting to speculate that these data explain the correlation
found between C/EBPδ expression and lymph node invasion observed in our patient cohort. Indeed,
anchorage-independent growth is strongly associated with the metastatic potential of cancer cells [44].
Irrespective of the actual mechanism, the reduced overall survival in pancreatic ductal adenocarcinoma
patients with low C/EBPδ levels might be directly linked to the increased lymph node metastases in
these patients.
Taken together, our results point towards a clear direction where C/EBPδ regulates the proliferation
and clonogenic capacities of PDAC cells. However, as two-dimensional monoculture experiments
in vitro cannot account for important factors, such as stromal and immune infiltration, in vivo validation
of these findings is urgently needed to manifest the notion that C/EBPδmight act as a tumor suppressor
in PDAC.
C/EBPδ is obviously not the first tumor suppressor identified in pancreatic adenocarcinoma.
Indeed, genes such as TP53, SMAD4, PTEN, and CDKN2A are well-known tumor suppressors
and mutations in these genes, which are present in over 70% of pancreatic ductal adenocarcinomas,
drive tumor progression. As opposed to the other classical tumor suppressors, C/EBPδ seems, however,
neither hypermethylated, nor mutated, lost or deleted in pancreatic adenocarcinoma (re-analysis of
previously published data [48–50]) suggesting re-activation of C/EBPδmay hold therapeutic promise in
the setting of pancreatic adenocarcinoma. Although C/EBPδ re-expression indeed limits proliferation
and clonogenicity in pancreatic adenocarcinoma cell lines, future studies should prove or refute
this hypothesis.
The mechanism via which C/EBPδ exerts its tumor suppressive and anti-metastatic effects remains
elusive. In an attempt to uncover the underlying mechanism, we have investigated the expression
of different putative targets of C/EBPδ involved in cell cycle progression, apoptosis, stemness
and the leading-edge genes of the above described gene set enrichment analyses (GSEAs) (Figure S5).
Enhanced expression of CDKN1A (p21) along with suppressed cyclin-dependent kinases CDK1,
CDK2 and CDK6 point towards cell cycle arrest as a main mechanism of the observed C/EBPδ-induced
effects in PDAC cells. Interestingly, however, C/EBPδ also appears to affect almost all of the other
investigated pathways to some degree. Hence, the data are not as straightforward as expected and do
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not allow firm conclusions on the downstream pathways affected by C/EBPδ. High-throughput
RNAseq experiments will be deployed to uncover the major driving mechanism underlying C/EBPδ’s
role in PDAC. These will be valuable in the view of molecular biology as well as for the discovery of
new clinical targets in the treatment of PDAC.
To date, several agents have been described to effectively induce C/EBPδ expression. Among these
activators are interleukin-6, which elicited growth-inhibiting effects on LNCaP prostate cancer cells via
C/EBPδ activation [51], 1-(2-hydroxy-5-methylphenyl)-3-phenyl-1, 3-propanedione (HMDB), which
attenuated the growth of A431 epidermoid carcinoma xenografts in severe combined immunodeficient
mice [18,27], and metformin, which induced autophagy of Huh7 liver cancer cells via C/EBPδ
activation [52]. Next to that, C/EBPδ has been induced by various external stimuli in the inflammatory
context [53]. Preliminary experiments did not show a significant effect of any of these compounds on
CEBPD expression in pancreatic adenocarcinoma cells and further studies are needed to find potent
upstream regulators of C/EBP δ in this context.
In contrast to our observation that the loss of C/EBPδ is associated with increased lymph node
metastasis and subsequent poor prognosis, it has recently been shown that C/EBPδ amplification
drives tumor metastasis in urothelial carcinoma [31]. These latter data are in line with a study showing
that C/EBPδ over-expression correlates with poor prognosis in glioblastoma [29]. A picture thus
emerges that C/EBPδmay act either as a tumor suppressor or as an oncogene in a context-dependent
manner. In line with this notion, we show here that C/EBPδ levels in two other tumors that are located
within the pancreas, i.e., ampullary carcinoma and intrapancreatic cholangiocarcinoma, do not differ
significantly from control levels in normal intestinal epithelial cells and cholangiocytes, respectively.
More importantly, we could not identify a correlation of either patient survival or lymph node status
with C/EBPδ expression in ampullary carcinoma or intrapancreatic cholangiocarcinoma patients based
on which we propose that C/EBPδ is unlikely to act as a tumor suppressor in these cancers. Although
it may be tempting to suggest that the baseline expression of C/EBPδ in healthy tissues can generally
determine the sensitivity of an arising tumor to the tumor suppressive effects of C/EBPδ, the questions of
what determines whether C/EBPδ acts as tumor promotor or tumor suppressor remains to be answered.
4. Materials and Methods
4.1. Mining of Publicly Available RNA Microarray Datasets
Datasets were derived from Gene Expression Omnibus [48] using the R2 microarray analysis
and visualization platform [46]. CEBPD expression levels were derived from two different datasets,
i.e., GSE62452 (updated version of GSE28735 [33] with an extra 16 tumor and control biopsies)
and GSE16515 [34]. From the GSE16515 dataset, we only included patients of which paired tumor
and adjacent non-tumor biopsies were available. Gene set enrichment analysis (GSEA) was performed
using the Broad Institute tool [49]. Samples were dichotomized by median CEBPD expression.
p-values indicating the significance of enrichment were determined by 1000 permutations using
the Ben-Porath [35] and Chiang [36] proliferation gene sets.
4.2. Tissue Microarray (TMA)
Formalin-fixed, paraffin-embedded biopsies from 129 pancreatic cancer cases between the years
of 1983 and 2015 were used for compilation of tissue microarrays (TMAs) using routine procedures.
Biopsies were selected from the archives of the Pathology Department at the Amsterdam University
Medical Center, Amsterdam. The study was approved by the investigator’s institutional review
boards. Patients with a known previous malignancy in another organ were excluded from the analysis.
The current study included 89 men (69.8%) and 40 women (30.2%), their ages range from 47 to
83 years, with a mean (±SD) of 64.4 (±8.9) and median of 65 years (Table 2). Sixty-seven patients
were diagnosed with pancreatic ductal adenocarcinoma, 42 with ampullary carcinoma and 20 with
intrapancreatic cholangiocarcinoma. For 104 of the patients, 3 cores were available each (43 pancreatic
Cancers 2020, 12, 2546 13 of 21
ductal adenocarcinoma, 20 intrapancreatic cholangiocarcinoma, 41 ampullary carcinoma). Each
core received an individual score as described in 4.4. For 25 patients, only one core was available
(24 pancreatic ductal adenocarcinoma, 1 ampullary carcinoma). From each of these cores, three
tumor-cell containing locations were selected at random and nuclear C/EBPδ staining was quantified
as described in 4.4. Six biopsies of normal pancreas tissue were included to serve as healthy control
and C/EBPδ staining was quantified as described in 4.4.
Table 2. Characteristics of patients included in the cohort.
Characteristic
PDAC (N = 67) AC (N = 42) IP CCA (N = 20)
N % N % N %
Median age
(range) (years)
63
(47–83)
66.5
(48–78)
64.5
(49–82)
Sex (M/F) (49/18) (73.2/26.8) (28/14) (66.7/33.3) (12/8) (60/40)
Surgery
PPPD 59 88.1 39 92.9 18 90
Whipple–Kausch 8 11.9 3 7.1 2 10
Radicality
R0 (≤1mm) 32 47.8 38 90.5 15 75
R1 (<1mm) 27 40.3 4 9.5 5 25
Dubious 8 11.9 0 0 0 0
Diameter post-op (cm)
1–2 1 1.5 N/A N/A
2–4 34 50.7 N/A N/A
4–6 17 25.4 N/A N/A
N/A 15 22.4
N-stage
N0 15 22.4 27 64.3 8 40
N1 52 77.6 15 35.7 12 60
Grading
Well differentiated 2 3 N/A N/A
Moderately differentiated 18 26.9 N/A N/A
Poorly differentiated 21 31.3 N/A N/A
N/A 26 38.8
Survival
Median
(range) (months)
18.33
(1.58–88.9)
49.92
(6.6–127.38)
24.36
(1.97–103.36)
4.3. Immunohistochemistry
C/EBPδ stainings were performed essentially as described before [54–57] with minor modifications.
Four micron-thick paraffin embedded tissue sections were deparaffinized and treated with 0.3% H2O2
in methanol for 15 min to block endogenous peroxidase activity. Subsequently, slides were blocked with
Ultra V block (#TA-125-UB; Thermo Fisher Scientific, Waltham, MA, USA) and incubated with a rabbit
polyclonal antibody against C/EBPδ (#GWB-MM818H; GenWay Biotech, San Diego, CA, USA) in a
1:1000 dilution in PBS at 4 ◦C overnight. The next day, slides were incubated with Powervision poly-HRP
anti rabbit IgG (#DPVM-55HRP; Immunologic, Duiven, Netherlands) for 30 min at room temperature
and stained using 3,3’Diaminobenzidine (Bright DAB, #BS04-999; Immunologic). Hematoxylin (1:10 in
demineralized H2O) was applied as counterstaining.
4.4. Quantification of C/EBPδ Protein Levels
C/EBPδ-stained slides were reviewed by three independent pathologists in a blinded fashion to
the clinical status of the patients. Specimens with conflicting scores were re-evaluated until consensus
was reached. Nuclear C/EBPδ expression in tumor cells was scored based on the percentage of
positively stained nuclei and the intensity of the positive staining. The percentage of positive nuclei
for each core was scored on a scale from 0 to 3 (0: no positive nuclei, 1: less than 30% positive
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nuclei, 2: between 30–70% positive nuclei, 3: more than 70% positive nuclei) whereas the intensity of
the positive nuclei was scored on a scale from 1 to 3 (1: low intensity, 2: intermediate intensity, 3: high
intensity). The intensity score (i.e., the average score of 10 randomly selected cells in three different
areas of each core) was finally multiplied by the percentage score leading to a theoretical maximum
score of 9. For survival analysis Kaplan–Meier curves were constructed using GraphPad Prism 6.0
(GraphPad Software Inc., La Jolla, CA, USA) whereby C/EBPδ expression levels were divided into an
upper and a lower half based on the range observed in each type of tumor.
4.5. Cell Lines and Cell Culture Reagents
Human PANC-1, MIA PaCa-2 and CAPAN-2 pancreatic cancer cell lines (ATCC, Manassas, VA,
USA) were cultured in high glucose in Dulbecco’s Modified Eagle Medium (Gibco, Thermo Fischer
Scientific, Waltham, MA, USA) supplemented with 10% (v/v) fetal calf serum (FCS; Serana, Pessin,
Germany), 2% (v/v) penicillin–streptomycin (Gibco, Thermo Fischer Scientific, Waltham, MA, USA)
and 2 mM L-glutamine (Lonza, Basel, Switzerland). Cells were incubated in 5% CO2 incubators
at 37 ◦C. All cell lines were tested mycoplasma-negative and their identities have been confirmed
by STR-profiling.
4.6. RNA Isolation, cDNA Synthesis and RT-qPCR
To determine mRNA expression levels, RNA was extracted using the NucleoSpin® RNA-extraction
Kit (Macherey-Nagel GmbH and Co. KG, Düren, Germany), according to the supplier’s protocol
for cultured cells. Eluted RNA was analyzed spectrophotometrically using the NanoDrop 2000.
All samples were treated with RQ1 RNAse-Free DNAse (Promega Benelux BV, Leiden, Netherlands)
and reverse-transcribed into cDNA using M-MLV Reverse Transcriptase (Promega Benelux BV,
Leiden, Netherlands), random hexamers (Fisher scientific, Landsmeer, Netherlands) and 10 mM
dNTPs (Fermentas, Fisher scientific, Landsmeer, Netherlands). The SensiFAST™ SYBR® No-ROX
Kit (GC biotech, Waddinxveen, Netherlands) was used to perform real-time quantitative RT-PCR
on a LightCycler® 480 Instrument II (Roche Molecular Systems, Inc., Almere, Netherlands).
CEBPD expression levels were normalized to the expression of the reference genes TBP and GAPDH or
TBP (EGFP vs. CEBPD) using the following primers.
GAPDH forward primer (5′-3′): AAGGTGAAGGTCGGAGTCAAC;
GAPDH reverse primer (5′-3′): TGGAAGATGGTGATGGGATT;
TBP forward primer (5′-3′): ATCCCAAGCGGTTTGCTGC;
TBP reverse primer (5′-3′): ACTGTTCTTCACTCTTGGCTC;
CEBPD forward primer (5′-3′): GCAGAAGTTGGTGGAGCTGT;
CEBPD reverse primer (5′-3′): TTACCGGCAGTCTGCTGTC;
EGFP forward primer (5′-3′): AGCTGACCCTGAAGTTCATCTG;
EGFP reverse primer (5′-3′): AAGTCGTGCTGCTTCATGTG;
CDK1 forward primer (5′-3′): CCCTTTAGCGCGGATCTA;
CDK1 reverse primer (5′-3′): ATGGCTACCACTTGACCTGT;
CDK2 forward primer (5′-3′): GAAAAGATCGGAGAGGGCA;
CDK2 reverse primer (5′-3′): ACCCTCAGTCTCAGTGTCCA;
CDK4 forward primer (5′-3′): TCTATGGTCGGGCCCTCTG;
CDK4 reverse primer (5′-3′): TCAGATCAAGGGAGACCCT;
CDK6 forward primer (5′-3′): CTGCAGGGAAAGAAAAGTGC;
CDK6 reverse primer (5′-3′): TTCCCTCCTCGAAGCGAAG;
CDKN1A forward primer (5′-3′): GCATGATCTGAGTTAGGTCAC;
CDKN1A forward primer (5′-3′): GACATGGCGCCTGAACAGA;
BCL-2 forward primer (5′-3′): GGTGGGGTCATGTGTGTGG;
BCL-2 reverse primer (5′-3′): CGGTTCAGGTACTCAGTCATCC;
BCL-XL forward primer (5′-3′): AGAGAACAGGACTGAGGCCC;
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BCL-XL reverse primer (5′-3′): TCAAAGCTCTGATATGCTGTCCC;
CD44 forward primer (5′-3′): AAGGTGGAGCAAACACAACC;
CD44 reverse primer (5′-3′): CTGAGACTTGCTGGCCTCTC;
TOP2A forward primer (5′-3′): TACATCCAAGGGTGGCAGAC;
TOP2A reverse primer (5′-3′): CCTGATGTGCTTTTACTGCAACA;
TTK forward primer (5′-3′): CATCAACATGGCATTGTTCAC;
TTK reverse primer (5′-3′): TCTGGTTGCATTTGGTTTGC;
ASPM forward primer (5′-3′): GTTGCAGACAAAGGCGGAAG;
ASPM reverse primer (5′-3′): CCTACTTCGTACATCAGAGGCTC;
ANLN forward primer (5′-3′): TTCCCAAAGGGATGGCGATG;
ANLN reverse primer (5′-3′): GGAGAAGTAGCTTTCACAGAGC;
4.7. Gene Transfection and Transduction
PANC-1 cells were transfected with pHEF-1TIG-CEBPD-IRES-EGFP or pHEF-1TIG-IRES-EGFP
using the Biontex K2 transfection system (Biontex, München, Germany) according to the supplier’s
protocol. For constitutive over-expression of C/EBPδ, a third-generation lentiviral system using
pHEF-1TIG-CEBPD-IRES-EGFP or pHEF-1TIG-IRES-EGFP, pMDLg/pRRE (Addgene #12251), pRSV-Rev
(Addgene # 12253) and pMD2.G (Addgene #12259) was employed to stably transduce PANC-1
and MIA-PaCa-2 cells. We have found that lentivirus production was enhanced in HEK293T cells
expressing an shRNA targeting CEBPD (Figure S6B). Therefore, we used HEK293T cells stably
transduced with an shRNA targeting CEBPD (MERCK MISSION® TRC-No, TRCN0000013969, clone ID
NM_005195.2-271s1c1) for all lentivirus productions. These producer cells were transfected for lentiviral
production using LipofectamineTM 2000 Transfection Reagent (Figure S6A). The viral supernatant was
collected 48 and 72 h after transfection, the virus was precipitated using PEG-it™ Virus Precipitation
Solution (System Bioscience, Cat No. LV810A-1) at 4 ◦C over the weekend and resuspended in 1/100 of
the original volume. Then, 100 µL was used to transduce 750,000 HEK293T cells in a 6-well plate by
addition of the viral medium 24 h after seeding. For inducible over-expression of C/EBPδ, the CEBPD
cDNA was cloned into the pCW57 vector (Addgene # 80921) containing a doxycycline-controlled
transactivator (tTA) that binds to the TRE promoter to initiate transcription of C/EBPδ. This vector
was used with the same third-generation lentiviral system as above and prepared in the same way.
Then, 25 µL virus-containing medium was used to transduce 100,000 PANC-1 or MIA PaCa-2 cells
in a 24-well plate. Forty-eight hours after transduction, cells were passaged and selected using 20 or
5 µg/mL Blasticidin (Invitrogen # ant-bl-05). Single cells were seeded in 96-well plates and allowed
to grow out. Per cell line, a pool of three clones with high inducibility and low leakiness of C/EBPδ
expression was selected for subsequent experiments.
4.8. Fluorescent Activated Cell Sorting
Forty-eight hours after transduction, the transduced cells were trypsinized and re-suspended in
fluorescent activated cell sorting (FACS) buffer (PBS containing 1% FCS). The SONY SH800S Cell Sorter
with single-cell sorting for clonogenic assays or two-way sorting to divide cells into EGFP-expression
fractions was used. For MIA PaCa-2 cells, a 100 µm sorting chip was used and for PANC-1 cells,
a 130 µm sorting chip was used. For RNA extraction, cells were sorted into RA1 lysis buffer (from
NucleoSpin® RNA-extraction Kit, Ref. 740955, Macherey-Nagel GmbH and Co. KG, Düren, Germany)
and further processed for RNA extraction and quantitative RT-PCR.
4.9. Clonogenic Assay
Respective of the experiment, 100 cells were seeded into 24-well plates or 500 cells into a 12-well
plate. Visible colonies were formed after two weeks. At this point, cells were fixed and stained using
crystal violet (0.5% crystal violet in 30% ethanol/3% formaldehyde) for 10 min at room temperature
followed by two washes in tap water. The colonies in 24-well plates were counted manually,
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only including those that count at least 50 cells. Colonies in the 12-well plate were additionally counted
and measured using countPHICS [58].
4.10. Western Blot
Total protein was extracted by lysing cells in RIPA buffer (150 mM sodium chloride, 1% Triton
X-100, 0.5% sodium deoxycholate, 0.1% SDS and 50 mM Tris (pH8.0)). Upon addition of Laemmli
buffer (200 mM Tris-Cl (pH 6.8), 8% SDS, 0.4% Bromophenol blue and 40% glycerol) containing 2%
2-Mercaptoethanol, samples were fractionated by SDS/PAGE and transferred onto Immobilon-FL
membranes (Millipore, Darmstadt, Germany). The blot was blocked in 5% BSA in PBS for 1 h at
room temperature and incubated with primary antibodies against C/EBPδ (Santa Cruz Biotechnology,
sc-365546, 1:500), eGFP (GeneTex, GTX26556, 1:5000) and α-tubulin (Santa Cruz Biotechnology, sc-23948,
1:1000) in TBS with 0.1% Tween-20 over night at 4 ◦C. The blot was then washed in TBS with 0.1%
Tween-20, incubated with secondary HRP-linked antibodies anti-rabbit-IgG (Cell Signaling, #7074,
1:1000) or anti-mouse-IgG (DAKO, P0447, 1:2500) for 1 h at room temperature in TBS with 0.1% Tween-20,
washed again and incubated with ECL Western Blotting Substrate (Pierce, #32106, Thermo Fisher) for
10 min. The blot was imaged using the ImageQuant LAS 4000 (GE Healthcare Life Sciences, Eindhoven,
Netherlands).
To visualize small differences of protein expression in doxycycline-induction experiments
(Figure 5D,F), these Western blots were performed using the Wes™ Simple Western capillary-based
automated immunoblotting system according to the standard protocol recommended by the supplier.
The resulting images were processed using the Compass software for Simple Western (ProteinSimple,
San Jose, CA, USA).
4.11. Proliferation Assay
To assess the proliferative capacity of cell lines upon re-expression or knock-down of C/EBPδ,
10,000 cells (MIA PaCa-2 and PANC-1 transduced with a doxycycline-inducible over-expression plasmid
or an empty control plasmid (pCW57 plasmid, Addgene # 80921)) or 50,000 cells (Capan-2 transduced
with shRNAs against C/EBPδ or tGFP) were seeded in 24-well plates in complete cell culture medium as
described above or in the presence of 2000 ng/mL doxycycline (#D9891, Sigma-Aldrich N.V. Zwijndrecht,
Netherlands) for 5 days (MIA PaCa-2 and PANC-1) and 8 days (Capan-2). Plates were scanned using
the IncuCyte® S3 Live-Cell Analysis System (Sartorius, Göttingen, Germany). The confluence of
experimental conditions was normalized to the respective control cell line.
4.12. Soft Agar Tumor Sphere Formation Assay
From an autoclaved 5% agar (#30391-049, Thermo Fischer Scientific, Waltham, MA, USA) solution
in saline, a 0.5% agar solution in Dulbecco’s Modified Eagle Medium (Gibco, Thermo Fischer
Scientific, Waltham, MA, USA) was prepared and 800 µL was pipetted into 12-well plates to
form a semi-solid bottom layer. From the same stock solution, three 0.3 % agar solutions were
prepared in complete cell culture medium as described in Section 4.5 and supplemented with either
no doxycycline, 100 ng/mL doxycycline or 2000 ng/mL doxycycline (#D9891, Sigma-Aldrich N.V.
Zwijndrecht, Netherlands). Respectively, 6000 MIA PaCa-2 cells or 10,000 PANC-1 cells, each transduced
with either a doxycycline-inducible C/EBPδ over-expression plasmid or an empty control plasmid
(pCW57 plasmid, Addgene # 80921) were added to 10 mL of 0.3% agar solution supplemented with or
without doxycycline. Of the individual suspensions, 800 µL was pipetted in triplicate onto the solidified
0.5% bottom layers and left to solidify. Wells were covered with complete cell culture medium
supplemented with the respective concentration of doxycycline. Fresh medium was added twice per
week without doxycycline or supplemented with 200 ng/mL or 4000 ng/mL doxycycline to ensure
sufficient diffusion of doxycycline to the embedded cells. MIA PaCa-2 and PANC-1 cells were allowed
to form tumor spheres for two and three weeks, respectively. All wells were then scanned using
the EVOS® FL Cell Imaging System at 4× magnification using bright field microscopy, to capture
Cancers 2020, 12, 2546 17 of 21
all tumor spheres in a single plane. Spheres were then counted in Adobe Photoshop CS6 (Adobe®
Photoshop® 2020 for Windows, San Jose, CA, USA) using the quick selection tool which was set to a
diameter 23 px corresponding to 150 µm to count all spheres of this size and larger. The experiment
was conducted 3 times.
4.13. Knock-down of C/EBPδ in CAPAN-2 Cells
To knock down C/EBPδ in Capan-2 cells, a third-generation lentiviral system using pLKO.1
puro (#8453 Addgene) containing shRNAs against CEBPD or tGFP were used. Glycerol stocks
were purchased from Sigma-Aldrich (St. Louis, MO, USA) (MISSION shRNA library). We selected
clones TRCN0000013695 (shCEBPD #1), TRCN0000013696 (shCEBPD #2), TRCN0000013693 (shCEBPD
#3) and TRCN0000013694 (shCEBPD #4) against CEBPD and SHC004 against turboGFP as control.
Bacteria were seeded on agar plates containing 100 ng/mL ampicillin and single colonies were expanded
in liquid cultures. Plasmids were purified (NucleoSpin® DNA, RNA and protein purification Kit,
Ref. 740588.50, Macherey-Nagel GmbH and Co. KG, Düren, Germany) and incorporated in a 3rd
generation lentivirus using pMDLg/pRRE (Addgene #12251), pRSV-Rev (Addgene # 12253) and pMD2.G
(Addgene #12259). Lentiviruses were produced as described in Section 4.7 in normal HEK293T
cells and Capan-2 cells were transduced in the same manner as described above and selected using
Puromycin 1 µg/mL.
4.14. Data Analysis
Statistical analyses were performed using GraphPad Prism 6.0 (GraphPad Software Inc., La Jolla,
CA, USA). Using SPSS, the data were tested for significant outliers which were excluded from further
analysis. Microarray data were analyzed using paired t-tests. Immunohistochemistry data and N-status
were analyzed using the Mann–Whitney U test. Kaplan–Meier survival curves were analyzed using
the Mantel–Cox log rank test. C/EBPδ-expression was correlated to lymph node involvement using
a one-sided Fisher’s exact test. Survival data among CEBPD-low and CEBPD-high groups were
compared using the Mann–Whitney U test. For in vitro experiments, data were analyzed using
the Mann–Whitney U tests whereby a one-tailed p-value is given for the reduction in clonal outgrowth
upon C/EBPδ over-expression. Pearson correlation was used to correlate CEBPD and EGFP expression,
p-values are one-tailed. CEBPD mRNA values of Capan-2 knock-down cell lines were tested for
normality using the Shapiro–Wilk test and two-tailed p-values were calculated using a parametric
t-test. Two-way ANOVA with Greenhouse–Geisser correction was used to compare growth curves.
Statistical significance was set at p < 0.05.
5. Conclusions
Pancreatic ductal adenocarcinoma is the most common and most fatal form of pancreatic cancer
and, to date, only few tumor suppressor genes, including TP53, SMAD4, PTEN and CDKN2A,
are formally established in this context [12,13]. Here, we have identified C/EBPδ as a novel putative
tumor suppressor gene that is downregulated in pancreatic ductal adenocarcinoma but not in ampullary
carcinoma or intrapancreatic cholangiocarcinoma. With this discovery, we add valuable insights to
the biology of pancreatic cancer and the complex context-dependent role of C/EBPδ in tumorigenesis
in general, and stress that this heterogeneity should be considered in clinical practice. Maybe more
importantly, we have shown that re-expressing C/EBPδ limits pancreatic cancer cell growth in a
dose-dependent manner, implying that re-expressing C/EBPδ in pancreatic ductal adenocarcinoma may
limit disease progression, although this remains to be established in ongoing preclinical experimental
animal studies.
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